Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Oct;98(10):1037-41.
doi: 10.1111/j.1471-0528.1991.tb15343.x.

A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue

C J Gallagher  1 , R T Oliver, D H Oram, C G Fowler, P R Blake, B S Mantell, M L Slevin, H F Hope-Stone
Affiliations

A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue

C J Gallagher et al. Br J Obstet Gynaecol. 1991 Oct.

Abstract

Objective: To test the antitumour effect of gonadotrophin releasing-hormone (GnRH) analogues in women with recurrent endometrial cancer.

Design: An open phase II observational trial of GnRH analogues. Serial measurements of gonadotrophins, sex hormones and tumour dimensions were made together with repeat biopsy when possible to assess the response to treatment.

Setting: The outpatient clinics of the Department of Medical Oncology at The Royal London, Royal Marsden and St Bartholomew's hospitals.

Subjects: 17 patients with endometrial cancer which had recurred after surgery, radiotherapy and progesterone treatment and was symptomatic, progressive and assessable for response.

Intervention: Monthly subcutaneous injection of GnRH analogue.

Main outcome measures: Reduction in serum gonadotrophins and reduction in tumour dimensions.

Results: Six out of 17 patients (35%, 95% CI 12.6-58%) achieved a complete or partial remission which continues for a median of 20 months with no adverse effects.

Conclusion: GnRH analogues have a significant antitumour effect in recurrent endometrial cancer which warrants further examination in comparison with progestogens.

PubMed Disclaimer

Substances